[1]JIANG XJ，WANG J，DENG XY，et al.Immunotherapy targeted to immune checkpoint：A revolutionary breakthrough in cancer therapy［J］.Prog Biochem Biophys，2018，45(11)：1178-1186.
[2]WEI F，WU Y，TANG L，et al.BPIFB1(LPLUNC1) inhibits migration and invasion of nasopharyngeal carcinoma by interacting with VTN and VIM［J］.Br J Cancer，2018，118(2)：233-247.
[3]WANG JP，TANG YY，FAN CM，et al.The role of exosomal non-coding RNAs in cancer metastasis［J］.Oncotarget，2018，9(15)：12487-12502.
[4]WANG M，ZHAO J，ZHANG L，et al.Role of tumor microenvironment in tumorigenesis［J］.J Cancer，2017，8(5)：761-773.
[5]SHAO C，YANG F，MIAO S，et al.Role of hypoxia induced exosomes in tumor biology［J］.Mol Cancer，2018，17(1)：120.
[6]HOFMEYER KA，JEON H，ZANG X.The PD-1/PD-L1(B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion［J］.J Biomed Biotechnol，2011，2011：451694.
[7]PATSOUKIS N，LI L，SARI D，et al.PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2［J］.Mol Cell Biol，2013，33(16)：3091-3098.
[8]WARTEWIG T，KURGYIS Z，KEPPLER S，et al.PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis［J］.Nature，2017，552(7683)：121-125.
[9]SETO T，SAM D，PAN M，et al.Mechanisms of primary and secondary resistance to immune checkpoint inhibitors in cancer［J］.Medical Sciences，2019，7(2)：14.
[10]REKIK R，BELHADJ HMIDA N，BEN HMID A，et al.PD-1 induction through TCR activation is partially regulated by endogenous TGF-β［J］.Cell Mol Immunol，2015，12(5)：648-649.
[11]BALLY AP，TANG Y，LEE JT，et al.Conserved region C functions to regulate PD-1 expression and subsequent CD8 T cell memory［J］.J Immunol，2017，198(1)：205-217.
[12]CHO HY，LEE SW，SEO SK，et al.Interferon-sensitive response element(ISRE) is mainly responsible for IFN-alpha-induced upregulation of programmed death-1(PD-1) in macrophages［J］.Biochim Biophys Acta，2008，1779(12)：811-819.
[13]TERAWAKI S，CHIKUMA S，SHIBAYAMA S，et al.IFN-γ directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity［J］.J Immunol，2011，186(5)：2772-2729.
[14]BOMMARITO D，HALL C，TAAMS LS，et al.Inflammatory cytokines compromise programmed cell death-1(PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1［J］.Clin Exp Immunol，2017，188(3)：455-466.
[15]DENG XY，XIONG F，LI X，et al.Application of atomic force microscopy in cancer research［J］.J Nanobiotechnology，2018，16(1)：102.
[16]SPACCARELLI N，ROOK AH.The use of interferons in the treatment of cutaneous T-cell lymphoma［J］.Dermatol Clin，2015，33(4)：731-745.
[17]MANDAI M，HAMANISHI J，ABIKO K，et al.Dual faces of IFN-γ in cancer progression：A role of PD-L1 induction in the determination of pro-and antitumor immunity［J］.Clin Cancer Res，2016，22(10)：2329-2334.
[18]BO H，FAN L，LI J，et al.High expression of lncRNA AFAP1-AS1 promotes the progression of colon cancer and predicts poor prognosis［J］.J Cancer，2018，9(24)：4677-4683.
[19]WANG X，YANG L，HUANG F，et al.Inflammatory cytokines IL-17 and TNF-a up-regulate PD-L1 expression in human prostate and colon cancer cells［J］.Immunol Lett，2017，184：7-14.
[20]ZHANG N，ZENG Y，DU W，et al.The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer［J］.Int J Oncol，2016，49(4)：1360-1368.
[21]SHEN MJ，XU LJ，YANG L，et al.Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway［J］.Oncotarget，2017，8(46)：80506-80520.
[22]XU L，CHEN X，SHEN M，et al.Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels［J］.Mol Oncol，2018，12(3)：269-286.
[23]ERIKSSON E，MILENOVA I，WENTHE J，et al.IL-6 signaling blockade during CD40-mediated immune activation favors antitumor factors by reducing TGF-β，collagen type I，and PD-L1/PD-1［J］.The Journal of Immunology，2019，202(3)：787-798.
[24]WANG Y，HU J，WANG Y，et al.EGFR activation induced snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells［J］.Cell Cycle，2018，17(12)：1457-1470.
[25]WANG J，JIA Y，ZHAO S，et al.BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer［J］.Oncogene，2017，36(45)：6235-6243.
[26]LI J，GU J.PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors：A meta-analysis［J］.Future Oncology，2019，15(14)：1667-1678.
[27]CASEY SC，TONG L，LI Y，et al.MYC regulates the antitumor immune response through CD47 and PD-L1［J］.Science，2016，352(6282)：227-231.
[28]SHAO C，YANG F，MIAO S，et al.Role of hypoxia-induced exosomes in tumor biology［J］.Mol Cancer，2018，17(1)：120.
[29]GU W，WANG L，WU Y，et al.Undo the brake of tumour immune tolerance with antibodies，peptide mimetics and small molecule compounds targeting PD-1/PD-L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells［J］.Clinical and Experimental Pharmacology & Physiology，2019，46(2)：105-115.
[30]HADERK F，SCHULZ R，ISKAR M，et al.Tumor-derived exosomes modulate PD-L1 expression in monocytes［J］.Sci Immunol，2017，2(13)：5509.
[31]GABRUSIEWICZ K，LI X，WEI J，et al.Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes［J］.Oncoimmunology，2018，7(4)：e1412909.
[32]CHEN G，HUANG AC，ZHANG W，et al.Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response［J］.Nature，2018，560(7718)：382-386.